Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix Injection Techniques in Prostate Cancer
NCT02526784Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- May 2017
- Modality
- Peptides, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of degarelix in prostate cancer (PCa) (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Patient Reported Injection Site Pain Score at Month 6. Started Dec 2015; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02526784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02526784.